Altimmune, Inc: Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

7 articles · 7 sources · updated 6 hours ago

Recent

finanznachrichten.deAltimmune, Inc: Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder6 hours ago

0

ts2.techAltimmune (NASDAQ:ALT) shares rise following alcohol-use disorder trial, with attention turning to $225 million in warrants6 hours ago · By Jerzy Lewandowski

0

GuruFocusAltimmune (ALT) Reports Positive Phase 2 Results for Pemvidutide in Alcohol Use Disorder7 hours ago

0

seekingalpha.comAltimmune rises as GLP-1 cuts drinking in mid-stage trial7 hours ago

0

marketwatch.comAltimmune Shares Jump Premarket After Positive Results in Phase 2 Trial of Pemvidutide7 hours ago

0

markets.businessinsider.comAltimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder12 hours ago

0

kfgo.comAltimmune drug cuts heavy drinking in mid-stage trial for alcohol use disorder13 hours ago

0